Therapeutic potential of cannabinoid receptor ligands: Current status

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 3, 2006, Pages 177-183

  Singh, J ^a   Budhiraja, Salil ^a,b  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b Shiksha Kunj Public School   (India)

Author keywords

Cannabinoid receptor; CB1 receptor; CB2 receptor; Rimonabant

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 ARACHIDONYLGLYCERYL ETHER; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; ARACHIDONOYL 2 CHLOROETHYLAMIDE; ARACHIDONYLCYCLOPROPYLAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; GUANINE NUCLEOTIDE BINDING PROTEIN; JWH 139; JWH 193; L 759633; L 759656; METHANANDAMIDE; NABILONE; O 1812; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANALGESIA; ANTIEMETIC ACTIVITY; ANXIETY DISORDER; APPETITE; ASTHMA; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RECEPTOR BINDING; EPILEPSY; EXTRACELLULAR SPACE; FIBROGENESIS; GASTROINTESTINAL DISEASE; GLAUCOMA; HEAD INJURY; HUMAN; HUNTINGTON CHOREA; HYDROLYSIS; IMMUNOCOMPETENT CELL; INFLAMMATION; MIGRAINE; MULTIPLE SCLEROSIS; NERVE CELL; OBESITY; OSTEOPOROSIS; PAIN; PARKINSON DISEASE; PENIS ERECTION; REVIEW; SCHIZOPHRENIA; SEXUAL FUNCTION; SPINAL CORD INJURY; WASTING SYNDROME;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; HUMANS; IMMUNE SYSTEM; LIGANDS; NEOPLASMS; NERVOUS SYSTEM DISEASES; PAIN; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 33745309883     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2006.28.3.985231     Document Type: Review

References (70)

1. Formukong, E.A., Evans, A.T., Evans, F.J. The medicinal uses of cannabis and its constituents. Phytother Res 1989, 3: 219-31.
2. Mechoulam, R., Ben-Shabat, S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis. Nat Prod Rep 1999, 16: 131-43.
3. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346: 561-4.
4. Munro, S., Thomas, K.L., Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365: 61-5.
5. Pertwee, R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999, 6: 634-64.
6. Di Mazro, V. Biosynthesis and inactivation of endocannabinoids relevance to their proposed role as neuromodulators. Life Sci 1999, 65: 645-55.
7. Pertwee, R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997, 74: 129-80.
8. Pertwee, R.G. Cannabinoid receptors and pain. Prog Neurobiol 2001, 63: 569-611.
9. Togentto, M., Amadest, S., Harrison, S., Trevisani, M., Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 2001, 21: 1104-9.
10. 2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 1997, 272: 21181-6.
11. Craib, S.J., Ellington, H.C., Pertwee, R.G., Ross, R.A. A possible-role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea pig bronchus. Br J Pharmacol 2001, 134: 30-7.
12. + channels. Receptors Channels 1999, 6: 363-74.
13. Maclennan, S.J., Reynen, P.H., Kwan, J., Bonhaus, D.W. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 1998, 124: 619-22.
14. Ross, R.A., Brockie, H.C., Stevenson, L.A. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 1999, 126: 665-72.
15. Pertwee, R.G. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp Opin Invest Drugs 2000, 9: 1553-71.
16. Molina-Holgado, E., Guaza, C., Borrell, J., Molina-Holgado, F. Effects of cannabinoids on the immune system and central nervous system: Therapeutic implications. Biodrugs 1999, 12: 317-26.
17. Huang C.-C., Lo, S.-W., Hsu, K.-S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synoptic transmission in rat striatal neurons. J Physiol 2001, 532: 731-48.
18. Melis, M., Gessa, G.L., Diana, M. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatr 2000, 24: 993-1006.
19. Beal, J.E., Olson, R., Lefkowitz, L. et al. Long term efficacy and safety of dronabinol for acquired immunodeficiency syndrome associated anorexia. J Pain Symptom Manage 1997, 14: 7-14.
20. Heshmati, H.M., Caplain, H., Bellisle, F., Mosse, M., Fauveau, C., Le Fur, G. SR 141716, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake, and body weight in overweight or obese men (abstract). Obes Res 2001, 9 (Suppl 1): S70.
21. Pagotto, U., Vicennati, V., Pasquali, R. The endocannabinoid system and the treatment of obesity. Ann Med 2005, 37: 270-5.
22. Di Carlo, G., Izzo, A.A. Cannabinoids for gastrointestinal diseases: Potential therapeutic applications. Exp Opin Invest Drugs 2003, 12: 39-49.
23. Massa, F., Marsicano, G., Herman, H. et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004, 113: 1202-9.
24. Izzo, A.A. Cannabinoids and intestinal motility: Welcome to CB2 receptors. Br J Pharmacol 2004, 142: 1201-2.
25. Formukong, E.A., Evans, A.T., Evans, F.J. Analgesic and antiinflammatory activity of the constituents of cannabis saliva. Inflammation 1988, 12: 361-71.
26. Hohmann, A.G., Suplita, R.L., Bolton, N.M. et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005, 435: 1108-12.
27. Costa, B., Trovato, A.E., Colleoni, M., Giagnoni, G., Zarini, E., Croci, T. Effect of the cannabinoid CB(1) receptor antagonist. SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005, 116: 52-61.
28. Fox, A., Bevan, S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Exp Opin Invest Drugs 2005, 14: 695-703.
29. Ocana, M., Cendan, C.M., Cobos, E.J., Entrena, J.M., Baeyens, J.M. Potassium channels and pain: Present realities and future opportunities. Eur J Pharmacol 500, 2004: 203-19.
30. Pertwee, R.G. Cannabinoid receptors and pain. Prog Neurobiol 63, 2001: 569-611.
31. Lupica, C.R., Riegel, A.C. Endocannabinoid release from mid-brain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 2005, 48: 1105-16.
32. Boyd, S.T., Fremming, B.A. Rimonabant-A selective CB1 antagonist. Ann Pharmacother 2005, 39: 684-90.
33. Martin, M., Ledent, C., Parmentier, M., Maldonado, R., Valverde, O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 2000, 12: 4038-46.
34. 2 receptors. Neuropsychopharmacology 2005, 30: 339-49.
35. Soria, G., Mendizabal, V., Tourino, C. et al. Lack of CB1 cannabinoid receptor impairs cocaine self administration. Neropsychopharmacology 2005, 30: 1670-80.
36. Van der Stelt, M., Veldhuis, W.B., Maccarrone, M. et al. Acute neural injury, excitotoxicity and endocannabinoid system. Mol Neurobiol 2002, 26: 317-46.
37. Marsicano, G., Goodenough, S., Monory, K. et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302: 84-8.
38. Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., Behl, C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002, 80: 448-56.
39. Panikashvili, D., Mechoulam, R., Beni, S.M., Alexaqndrovich, A., Shohami, E. CB1 cannabinoid receptor are involved in neuroprotection via NF-kappaB inhibition. J Cereb Blood Flow Metab 2005, 25: 477-84.
40. Khaspekov, L.G., Verca, M.S., Frumkina, L.E., Hermann, H., Marsicano, G., Lutz, B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 2004, 19: 1691-8.
41. Brotchie, J.M. CB1 cannabinoid receptor signaling in Parkinson's disease. Curr Opin Pharmacol 2003, 3: 54-61.
42. McCaw, E.A., Hu, H., Gomez, G.T., Hebb, A.L., Kelly, M.E., Denovan-Wright, E.M. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 2004, 271: 4909-20.
43. Ujike, H., Morita, Y. New perspectives in the studies on endocannabinoid and cannabis: Cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004, 96: 376-81.
44. Ujike, H., Takaki, M., Nakata, K. et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002, 7: 515-8.
45. Diana, M.A., Marty, A. Endocannabinoid-mediated short-term synaptic plasticity: Depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Phramacol 2004, 142: 9-19.
46. Azad, S.C., Monory, K., Marsicano, G. et al. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. Neuroscience 2004, 24: 9953-61.
47. Select Committee on Science and Technology. Cannabis: The scientific and medical evidence. The House of Lords Session 1997-98, 9th report [HL paper 151], The Stationary Office: London 1998.
48. Clofford, D.B. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983, 13: 669-71.
49. Katona, S., Kaminski, E., Sanders, H., Zajicek, J. Cannabinoid influence on cytokine profile in multiple sclerosis. Clinic Exp Immunol 2005, 140: 580-5.
50. Whally, B.J., Wilkinson, J.D., Williamson, E.M., Constanti, A. A novel component of cannabis extract potentiates excitatory synoptic transmission in rat olfactory cortex in vitro. Neurosci Lett 2004, 365: 58-63.
51. Maller, J., Bakos, N., Szirmay, M., Ledent, C., Freund, T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16: 1395-8.
52. Hirst, R.A., Lambert, D.G., Noteutt, W.G. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth 1988, 81: 77-84.
53. Akerman, S., Kaube, H., Goadsby, P.J. Anandamide is able to inhibit trigeminal neurons using an in vitro model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 2004, 309: 56-63.
54. Massi, P., Fuzio, D., Vigano, D., Sacerdote, P., Parolaro, D. Relative involvement of cannabinoid CB1 and CB2 receptors in delta9-tetrahydrocannbinol- induced inhibition of natural killer activity. Eur J Pharmacol 2000, 387: 343-7.
55. Roth, M.D., Baldwin, G.C., Tashkin, D.P. Effects of delta-9- tetrahydrocannabinol on human immune function and host defense. Chem phys lipids 2002, 121: 229-39.
56. Yuan, M., Kiertscher, S.M., Cheng, Q., Zoumalan, R., Tashkin, D.P., Roth, M.D. Delta9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002, 133: 124-31.
57. Siegmund, S.V., Uchinami, H., Osawa, Y., Brenner, D.A., Schwabe, R.F. Anandamide induces necrosis in primary hepatic-stellate cells. Hepatology 2005, 41: 1085-95.
58. Mimeault, M., Pommery, N., Wattez, N., Bailly, C., Henichart, J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003, 56: 1-12.
59. Lombard, C., Nagarkatti, M., Nagarkatti, P.S. Targeting cannabinoid receptors to treat leukemia: Role of cross-talk between extrinsic and intrinsic pathways in delta(9)-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 2005, 29: 915-22.
60. Petersen, G., Moesgaard, B., Schmid, P.C. et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J Neurochem 2005, 93: 299-309.
61. Sanchez, M.G., Sanchez, A.M., Ruiz-Llorente, L., Diaz-Laviada, I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett. 2003 18, 555: 561-6.
62. Green, K., Wynn, H., Bowman, K.A. A comparison of topical cannabinoids on the intraocular pressure. Exp Eye Res 1978, 27: 2 39-46.
63. Merritt, J.C., Perry, D.D., Russell, D.N., Jones, B.F. Topical delta9-tetrahydrocannabinol and aqueous humor dynamics in glaucoma. J Clin Pharmacol 1981, 21 (Suppl 8-9): 467S-71S.
64. Abboud, R., Sanders, H. Effect of oral administration of delta-9-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest 1976, 70: 480-5.
65. Williams, S., Hartley, J., Graham, J. Bronchodilator effect of delttetrahydrocannabinol administered by aerosol to asthmatic patients. Thorax 1976, 31: 720-3.
66. Steffens, S., Veillard, N.R., Arnaud, C. et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005, 434: 782-6.
67. Krylatov, A.V., Ugdyzhekova, D.S., Bernatskaya, N.A. et al. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 2001, 131: 523-5.
68. 1 receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br J Pharmacol 2004, 142: 701-8.
69. Melis, M.R., Succu, S., Mascia, M.S., Argiolas, A. Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection. Neurosci Lett 2004, 359: 17-20.
70. Idris, A.I., van't Hof, R.J., Greig, I.R. et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005, 11: 774-9.